I wouldn't be surprised if this will start soon with the earnings. The reliance on Humira is quite strong. There's not even common closer. Sky Ritzy and Renvak, which are the two newest products they are doing really well. It seems like all their portfolios seem to be growing slightly apart from hermitage. But all the rest of them seem to be doing quite steady. So it was a good steady earnings from Abbe. I would just like to see something similar to a compare these to Russia and see what Russia did.